High-sensitivity, multi-analyte, quantitative POCT enabled by D-IA
First written in FY2024. 3 of 7 entries say "Advanced", first in 2026-05-14. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「D-IA is being developed as a next-generation point-of-care testing (POCT) platform capable of measuring biomarkers in specimens with high accuracy and quantitatively. Its potential application across a broad range of disease areas, including not only infectious diseases but also chronic diseases such as dementia and diabetes, is being explored.」
The filing continues to indicate D-IA's high-precision quantitative testing capabilities and potential applications in chronic diseases, but does not specify a target achievement date or completion of commercialization. - FY2025RaisedAnnual report
「Up to 20 samples can be tested simultaneously by placing them in the chip-based reagent instrument, for example, up to 10 analytes simultaneously for samples from 2 people, or up to 5 analytes for samples from 4 people.」
D-IA’s simultaneous testing capacity expanded from up to 8 samples to up to 20. Specific use cases combining multiple people and analytes were added, and the company explains that both qualitative and quantitative testing are possible. - FY2024First statedAnnual report
「D-IA (digital immunoassay), currently under development, combines the simple operation of an antigen test kit with accuracy that can rival laboratory testing. Its key feature is the ability to perform tests rapidly using a compact, low-cost instrument. Up to 8 samples can be tested simultaneously by placing them in the disk-shaped instrument.」
The concept is designed to enable simple, laboratory-level testing in clinics, with up to 8 samples, up to 8 people per analyte, and both qualitative and quantitative testing.